1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A

300026.SZ
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class ACN flagShenzhen Stock Exchange
3.10
CNY
-0.06
- -
9.31BMarket Cap
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A
300026.SZ
(Shenzhen Stock Exchange)

Recent

price

3.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.17
0.25
0.52
0.84
1.13
1.25
1.29
1.12
1.4
1.74
2.15
2.57
2.24
2.05
2.69
- -
1.85
Revenue per Share
0.04
0.05
0.1
0.14
0.18
0.2
0.22
0.15
0.07
0.14
0.19
0.23
0.21
0.17
0.01
- -
-0.02
Basic EPS, GAAP
-0.03
-0.1
-0.03
0.01
-0.01
-0.04
0.01
0.12
0.03
-0.13
-0.12
-0.1
-0.01
0.4
0.31
- -
-0.06
Free Cash Flow per Basic Share
0.01
0.01
0.01
0.01
0.02
0.03
0.02
0.03
0.02
0.02
0.06
0.05
0.06
0.05
0.06
- -
0.04
Dividend per Share
0.14
0.2
0.32
0.47
0.69
0.99
1.75
1.86
1.91
2.12
2.14
2.33
2.5
2.63
3.61
- -
2.56
Book Value per Share
0.45
0.42
0.54
0.63
0.8
1.39
1.48
1.65
1.74
2.02
2.02
2.24
2.4
2.52
3.49
- -
2.48
Tangible Book Value per Share
2,279
2,291
2,364
2,505
2,530
2,675
2,993
3,005
3,011
2,875
3,018
2,988
2,973
2,980
2,147
1,850
3,016
Basic Weighted Avg Shares
384
562
1,229
2,097
2,864
3,348
3,867
3,374
4,224
5,003
6,488
7,671
6,650
6,109
5,783
- -
5,582
Sales/Revenue/Turnover
31.57
29.29
25.85
19.24
17.42
17.89
19.54
19.69
14.58
12.96
12.68
14.79
12.74
10.45
4.52
- -
3.32
Operating Margin (%)
11
16
21
43
50
57
95
109
131
156
190
261
307
346
347
- -
- -
Depreciation Expense
102
122
231
340
447
535
659
451
211
403
573
687
624
507
21
- -
-48
Net Income, GAAP
16
15.43
15.5
14.96
13.56
13.31
15.63
22.28
33.37
15.69
18.11
21.46
13.28
17.35
57.49
- -
49.4
Effective Tax Rate (%)
26.58
21.75
18.8
16.19
15.61
15.98
17.03
13.36
4.99
8.05
8.84
8.96
9.39
8.29
0.37
- -
-0.86
Profit Margin (%)
789
578
642
834
1,166
2,499
2,697
2,935
3,075
3,094
3,337
4,748
4,707
5,155
4,528
- -
4,512
Working Capital
- -
72
52
18
- -
5
- -
- -
- -
45
470
1,525
1,423
1,317
640
- -
495
LT Debt
1,098
1,050
1,387
1,703
2,204
5,290
6,039
6,509
6,576
7,070
7,392
7,952
8,463
8,868
8,799
- -
8,788
Total Equity
9.87
12.32
20.12
20.64
20.3
12.92
10.53
7.8
6.11
7.8
8.51
9.79
7.36
5.2
1.15
- -
- -
Return on Invested Capital (%)
28.96
17.81
26.84
32.22
28.02
21.91
15.2
7.85
3.5
6.3
8.33
8.72
7.32
5.85
0.43
- -
0.37
Return on Capital (%)
38.63
31.17
38.24
35.44
30.57
24.34
16.74
8.33
3.71
6.8
9.15
10.26
8.67
6.64
0.28
- -
-0.62
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
212
133
174
LT Borrowings
529
451
395
LT Finance Leases
111
105
100
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,004
3,004
3,004
Market Capitalization
11,014
10,799
11,131

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
6,149
6,084
6,032
Cash, Cash Equivalents & STI
1,306
1,187
1,327
Accounts Receivable, Net
2,656
2,694
2,620
Inventories
1,749
1,730
1,613
Total Current Liabilities
1,621
1,510
1,520
Payables & Accruals
- -
- -
- -
ST Debt
212
133
174
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,463
1,533
1,445
1,342
5,783
2025
1,393
1,402
- -
- -
- -
2026
1,130
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.01
2025
0.02
- -
- -
- -
- -
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.06
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Immunovia AB (IMMVF)
Crestchem Limited (CRSTCHM.BO)
Amicus Therapeutics, Inc. (0HF9.L)
Supriya Lifescience Ltd (SUPRIYA.BO)
Sunil Healthcare Ltd. (SUNLOC.BO)
Tsuruha Holdings Inc. (TSUSF)
Business
Tianjin Chase Sun Pharmaceutical Co.,Ltd Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) is a China-based company principally engaged in the research, development, production, and sale of pharmaceutical products and medical devices; its core offerings include traditional Chinese medicine formula granules, finished drugs such as blood purification injections, moxifloxacin hydrochloride injections (Anrotai), and low molecular weight heparin calcium injections (Bopuqing), raw pharmaceutical materials and excipients, medical devices, medical and health services, and smart supply chain solutions for pharmaceuticals and devices. The company operates primarily in China with a focus on therapeutic areas including immunity, cardiovascular and cerebrovascular diseases, respiratory system conditions, neurodegenerative diseases, anti-tumor treatments, sepsis, pulmonary hypertension, and infectious diseases; it maintains production facilities compliant with GMP standards for bulk drugs, capsules, granules, injections, and technology transfer services. Founded in 1996 and headquartered in Tianjin, China, the company listed on the Shenzhen Stock Exchange's GEM board in 2009 as a state-owned enterprise under local asset administration; it recently advanced clinical research on Xuebijing Injection for sepsis treatment published in eClinicalMedicine, participated in the 10th Smart Pharmaceutical Conference issuing the Tianjin Initiative on digitalization, joined the pharmaceutical industry new quality productive forces innovation community, and pursued strategic partnerships for market expansion while canceling a planned acquisition of additional stake in Hubei Enoray Biopharmaceutical.